🇺🇸 FDA

Intelligence · INN Directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed
4,797
Companies
1,769
Pipeline programs
20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 157 of 200 · A–Z by INN

  1. recombinant coronavirus (sars-cov-2) vaccine

    COVGOZE

    PMDA: approved

  2. recombinant human c1 inhibitor

    RHUCIN

    EMA: refused

    B06C

  3. recombinant respiratory syncytial virus pre-fusion f protein, adjuvanted with as01e

    AREXVY

    EMA: approved

    J07BX05

  4. recombinant salmon calcitonin

    FORCALTONIN

    EMA: withdrawn

    H05BA01

  5. reduced-dose

    NMPA: clinical trials

  6. refametinib

    NMPA: clinical trials

  7. regadenoson

    RAPISCAN

    INTRAVENOUS FDA: approved · EMA: approved

    C01EB21

  8. regdanvimab

    REGKIRONA

    EMA: withdrawn

    J06BD06

  9. regimen

    NMPA: clinical trials

  10. regimes

    NMPA: clinical trials

  11. regorafenib

    STIVARGA

    ORAL FDA: approved · EMA: approved · NMPA: clinical trials

    L01EX05

  12. regorafenib hydrate

    STIVARGA INITIAL APPROVAL

    PMDA: approved

  13. relacorilant

    LIFYORLI (COPACKAGED) CORCEPT THERAPEUTICS INC

    ORAL FDA: approved

  14. relatlimab

    OPDUALAG

    EMA: approved

    L01FY02

  15. relugolix

    ORGOVYX

    ORAL FDA: approved · EMA: approved · PMDA: approved · NMPA: clinical trials

    H01CC54

  16. relugolix + estradiol + norethisterone acetate

    RYEQO Gedeon Richter Australia Pty Ltd

    TGA: approved

  17. remdesivir

    VEKLURY

    INTRAVENOUS FDA: approved · EMA: approved · PMDA: approved

    J05AB16

  18. remibrutinib

    RHAPSIDO

    ORAL FDA: approved · EMA: approved

    L04AA60

  19. remicade

    NMPA: clinical trials

  20. remifentanil

    NMPA: clinical trials

  21. remifentanil hydrochloride

    REMIFENTANIL HYDROCHLORIDE

    INJECTION FDA: approved

  22. remimazolam

    BYFAVO

    EMA: approved · NMPA: clinical trials

    N05CD14

  23. remimazolam besylate

    BYFAVO

    INTRAVENOUS FDA: approved

  24. renin-angiotensin

    NMPA: clinical trials

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles — INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page — it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.

Data attribution and licensing: Data sources